Farmavita.Net - Pharmaceutical Licensing Network

Home

Farmavita.Net Journal

Hormonal Replacement Therapy

Business Reports - Market Report

Hormonal Replacement Therapy for Menopausal Symptoms - Safety fears continue to haunt the market

Sales of hormone replacement therapies treating menopausal symptoms have seen a sharp decline in recent years as a result of safety concerns raised by the Women's Health Initiative (WHI) study in 2002. Coupling this with Pfizer's acquisition of Wyeth, the leading estrogen manufacturer, the future direction of the market is uncertain.

Recovery of the HRT market following the WHI has been slow. In recent years an increase in sales in the USwhich remains the largest marketwas despite the continuous volume decrease.

Premarin remains the market leading drug accounting for over 37% of total sales in 2009 across the seven major markets. The difficulty in replicating the exact conjugated estrogen composition will continue to protect it from generic incursion for the foreseeable future.

The future of Aprela continues to be uncertain and the US Food and Drug Administration may decide not to approve the drug due to safety concerns. Nevertheless, should the drug launch Pfizer could drive market growth in an attempt to restore the multibillion market.

Read more...

Comments

Add New

RSS

Read also at Pharmaceutical Licensing Network

< Prev		Next >

Invite friends and business partners to join Farmavita.Net

Recommend Farmavita.Net and expand your network!

Go to "Expand Your Network" at Member Menu. There is invitation tool which will help you to import your e-mail addresses from internet or desktop address books. You will be connected to every invited person and also earn two "Good Karma" points for every new member.